AVISE Vasculitis AAV

The complete panel of ANCA-associated markers for a swift and accurate assessment of your patient’s disease state.

An advanced diagnostic test specifically designed to aid in the differential diagnosis of AAV. AVISE Vasculitis AAV exemplifies the rigorous quality that is at the core of all AVISE testing products.

AVISE Vasculitis AAV

The complete panel of ANCA-associated markers for a swift and accurate assessment of your patient’s disease state.

It is an advanced diagnostic test specifically designed to aid in the differential diagnosis of AAV. AVISE Vasculitis AAV exemplifies the rigorous quality that is at the core of all AVISE testing products.

Rapid and accurate testing is essential to prevent death and long-term disability from AAV

Signs and symptoms of ANCA-associated vasculitis (AAV) vary greatly and are not always indicative of the severity of the disease state.

ANNUAL INCIDENCE

per million¹

MORTALITY

25%

at five years¹

Rapid and accurate testing is essential to prevent death and long-term disability from AAV

Signs and symptoms of ANCA-associated vasculitis (AAV) vary greatly and are not always indicative of the severity of the disease state.

ANNUAL INCIDENCE

per million¹

MORTALITY

25%

at five years²

AVISE Vasculitis AAV

It is composed from the following markers:

Granulomatosis with polyangiitis (GPA)

Anti-PR3 antibodies are primarily associated with GPA and to a lesser extent, found in MPA (10%) and EPGA^3,7. However, anti-PR3 antibodies can also be seen in connective tissue disease, IBD, some infections, malignancy, and as a reaction to drugs⁴. Therefore, results should be interpreted with care in light of the clinical findings and workup⁶.

AVISE Vasculitis Test Report

Sample Test Report

References

Draibe JB, Fulladosa X, Cruzado JM, et al. Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis. Clin Kidney J. 2016;9(4):547-551. doi:10.1093/ckj/sfw056
Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S94-S104.1
Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): A multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunoˆuorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017;76(4):647-653. doi:10.1136/annrheumdis-2016-209507
Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999;111(4):507-13. doi: 10.1093/ajcp/111.4.507
Bossuyt X, Tervaert JW, Arimura Y, et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheum. 2017;13:683-692. doi: 10.1038/nrrheum.2017.140
Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ. 2020;368(March):1-16. doi:10.1136/bmj.m421
Mahler M, Radice A, Yang W, et al. Clinica Chimica Acta Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413(7-8):719-726. doi:10.1016/j.cca.2012.01.004
Mahler M, Radice A, Sinico RA, et al. Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. Nephrolog Dial Transplant. 2012;27(1):243-52. doi:10.1093/ndt/gfr203